RT Journal Article
SR Electronic
T1 Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263758
DO 10.1101/2021.09.17.21263758
A1 Pitisuttithum, Punnee
A1 Luvira, Viravarn
A1 Lawpoolsri, Saranath
A1 Muangnoicharoen, Sant
A1 Kamolratanakul, Supitcha
A1 Sivakorn, Chaisith
A1 Narakorn, Piengthong
A1 Surichan, Somchaiya
A1 Prangpratanporn, Sumalee
A1 Puksuriwong, Suttida
A1 Lamola, Steven
A1 Mercer, Laina D
A1 Raghunandan, Rama
A1 Sun, Weina
A1 Liu, Yonghong
A1 Carreño, Juan Manuel
A1 Scharf, Rami
A1 Phumratanaprapin, Weerapong
A1 Amanat, Fatima
A1 Gagnon, Luc
A1 Hsieh, Ching-Lin
A1 Kaweepornpoj, Ruangchai
A1 Khan, Sarwat
A1 Lal, Manjari
A1 McCroskery, Stephen
A1 McLellan, Jason
A1 Mena, Ignacio
A1 Meseck, Marcia
A1 Phonrat, Benjaluck
A1 Sabmee, Yupa
A1 Singchareon, Ratsamikorn
A1 Slamanig, Stefan
A1 Suthepakul, Nava
A1 Tcheou, Johnstone
A1 Thantamnu, Narumon
A1 Theerasurakarn, Sompone
A1 Tran, Steven
A1 Vilasmongkolchai, Thanakrit
A1 White, Jessica A
A1 Garcia-Sastre, Adolfo
A1 Palese, Peter
A1 Krammer, Florian
A1 Poopipatpol, Kittisak
A1 Wirachwong, Ponthip
A1 Hjorth, Richard
A1 Innis, Bruce L
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.17.21263758.abstract
AB Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It’s being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand.Methods This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg±CpG1018 (a toll-like receptor 9 agonist), 3 µg±CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov (NCT04764422).Findings Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation’s immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥4-fold increase over baseline.Interpretation NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2.Funding National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA)Competing Interest StatementPN, SSur, SPra, SPuk, RK, RSin, NS, SThe, TV, KP, and PW are salaried employees of the Government Pharmaceutical Organization. The vaccine administered in this study was developed by faculty members at the Icahn School of Medicine at Mount Sinai including FK, AGS, PP, and WS. Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and its faculty inventors could benefit financially. JSM and CLH are inventors on U.S. patent applications concerning the stabilized SARS-CoV-2 S construct.Clinical TrialNCT04764422Funding StatementFunding was reciveed from the National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, and the National Institutes of Health (USA). The funders of the study had no role in data collection, data analysis, or writing of the statistical report. GPO was the clinical trial sponsor and approved the study protocol. GPO employees contributed as authors by preparing the investigational vaccine, interpreting data, and writing this report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mahidol University IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available as appropiate.